Table 4.
Summary of VEGF Trials
| Trial | Patients | RR% (CR/PR) |
PFS (months) |
OS (months) |
Number (patients) |
Summary |
|---|---|---|---|---|---|---|
| Single Arm Phase 2 Perez et al. [61] |
Carboplatin plus paclitaxel and bevacizumab in unresectable metastatic melanoma | 17 | 6 | 12 | 53 | Carboplatin plus paclitaxel and bevacizumab was well tolerated and clinically beneficial |
| Randomized Phase 2 Kim et al. [62] |
Carboplatin plus paclitaxel and bevacizumab versus Carboplatin plus paclitaxel in untreated metastatic melanoma |
25.5 versus 16.4 |
5.6 versus 4.2 |
12.3 versus 8.6 |
214 | Carboplatin plus paclitaxel and bevacizumab demonstrated statistically significant improvement in OS |
| Single Arm Phase 2 Kottschade et al. [63] |
Carboplatin plus nab-paclitaxel in chemotherapy naïve(CN) and previously treated (PT) metastatic melanoma | 25.6 (CN) 8.8 (PT) |
4.5 (CN) 4.1 (PT) |
11.1 (CN) 10.1 (PT) |
41 (CN) 35 (PT) |
Carboplatin plus nab-paclitaxel has clinical activity in chemotherapy naïve patients |
| Single Arm Phase 2 Fruehauf et al. [64] |
Axitiniba in metastatic melanoma after maximum on one prior therapy | 18.8% | 3.9 | 6.6 | 32 | Axitinib demonstrated clinical activity in metastatic melanoma. |
aAxitinib is an oral second-generation inhibitor of VEGF receptors 1, 2, and 3. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response RR, response rate.